Micrometastases in Sentinel Lymph Nodes Represent a Significant Negative Prognostic Factor in Early-Stage Cervical Cancer: A Single-Institutional Retrospective Cohort Study.
cervical cancer
isolated tumor cells
micrometastasis
pathological ultrastaging
prognostic parameters
risk of recurrence
sentinel lymph node
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 May 2020
31 May 2020
Historique:
received:
15
04
2020
revised:
23
05
2020
accepted:
28
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
epublish
Résumé
The data on the prognostic significance of low volume metastases in lymph nodes (LN) are inconsistent. The aim of this study was to retrospectively analyze the outcome of a large group of patients treated with sentinel lymph node (SLN) biopsy at a single referral center. Patients with cervical cancer, stage T1a-T2b, common tumor types, negative LN on preoperative staging, treated by primary surgery between 01/2007 and 12/2016, with at least unilateral SLN detection were included. Patients with abandoned radical surgery due to intraoperative SLN positivity detected by frozen section were excluded. All SLNs were postoperatively processed by an intensive protocol for pathological ultrastaging. Altogether, 226 patients were analyzed. Positive LN were detected in 38 (17%) cases; macrometastases (MAC), micrometastases (MIC), isolated tumor cells (ITC) in 14, 16, and 8 patients. With the median follow-up of 65 months, 22 recurrences occurred. Disease-free survival (DFS) reached 90% in the whole group, 93% in LN-negative cases, 89% in cases with MAC, 69% with MIC, and 87% with ITC. The presence of MIC in SLN was associated with significantly decreased DFS and OS. Patients with MIC and MAC should be managed similarly, and SLN ultrastaging should become an integral part of the management of patients with early-stage cervical cancer.
Identifiants
pubmed: 32486512
pii: cancers12061438
doi: 10.3390/cancers12061438
pmc: PMC7352782
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Agentura Pro Zdravotnický Výzkum České Republiky
ID : No 16-31643A
Organisme : Agentura Pro Zdravotnický Výzkum České Republiky
ID : NV19-03-00023
Organisme : Univerzita Karlova v Praze
ID : UNCE 204065
Organisme : Univerzita Karlova v Praze
ID : PROGRES Q28/LF1
Organisme : The project "International Mobility of Researchers at Charles University" is supported by the Operational Programme Research, Development and Education
ID : reg. n. CZ.02.2.69/0.0/0.0/16_027/0008495
Références
J Clin Oncol. 2011 May 1;29(13):1686-91
pubmed: 21444878
Gynecol Oncol. 2013 Sep;130(3):525-9
pubmed: 23500089
Lancet. 2001 Jan 6;357(9249):15-20
pubmed: 11197354
Gynecol Oncol. 2008 Nov;111(2):276-81
pubmed: 18722005
Gynecol Oncol. 2011 Nov;123(2):230-5
pubmed: 21893335
Int J Gynaecol Obstet. 2016 Apr;133(1):69-75
pubmed: 26868069
Int J Gynecol Cancer. 2019 Mar;29(3):447-452
pubmed: 30833435
Gynecol Oncol. 2004 Apr;93(1):107-11
pubmed: 15047221
Gynecol Oncol. 1990 Sep;38(3):352-7
pubmed: 2227547
Int J Gynecol Cancer. 2020 Mar;30(3):364-371
pubmed: 31980488
Gynecol Oncol. 2017 Apr;145(1):96-101
pubmed: 28188015
Gynecol Oncol. 2010 Jan;116(1):33-7
pubmed: 19837449
Ann Surg Oncol. 2017 Oct;24(11):3406-3412
pubmed: 28785898
J Obstet Gynaecol Res. 2016 Jan;42(1):77-86
pubmed: 26554751
J Natl Compr Canc Netw. 2010 Dec;8(12):1435-8
pubmed: 21147906
Cancer. 2017 May 15;123(10):1751-1759
pubmed: 28117888
J Clin Oncol. 2008 Jun 20;26(18):2943-51
pubmed: 18565880
Gynecol Oncol. 2011 Mar;120(3):347-52
pubmed: 21216450
Obstet Gynecol. 2004 Jun;103(6):1204-10
pubmed: 15172853
Gynecol Oncol. 2005 Jun;97(3):727-32
pubmed: 15943983
Expert Rev Anticancer Ther. 2013 Jul;13(7):861-70
pubmed: 23875664
BMC Cancer. 2011 May 02;11:157
pubmed: 21529381
Int J Gynecol Pathol. 2015 Jul;34(4):379-84
pubmed: 26061072
Surg Oncol. 2008 Sep;17(3):227-35
pubmed: 18504122
Virchows Arch. 2018 Jun;472(6):919-936
pubmed: 29725757
Gynecol Oncol. 2018 Mar;148(3):456-460
pubmed: 29366509
Gynecol Oncol. 2009 Oct;115(1):46-50
pubmed: 19646741
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S147-8
pubmed: 16419199
Gynecol Oncol. 2010 May;117(2):266-9
pubmed: 20167355
Arch Pathol Lab Med. 2019 Dec 23;:
pubmed: 31869245
Gynecol Oncol. 2012 Mar;124(3):496-501
pubmed: 22120175
Ann Surg Oncol. 2013 Feb;20(2):413-22
pubmed: 22911367
Gynecol Oncol. 2006 Oct;103(1):35-44
pubmed: 16600355
Int J Gynecol Cancer. 1999 May;9(3):212-219
pubmed: 11240769
Gynecol Oncol. 2019 Jan;152(1):202-207
pubmed: 30318103
Lancet Oncol. 2008 Mar;9(3):297-303
pubmed: 18308255
Int J Gynecol Cancer. 2006 May-Jun;16(3):1188-94
pubmed: 16803505
Am J Surg Pathol. 2008 Sep;32(9):1336-43
pubmed: 18670356
Int J Gynecol Cancer. 2006 Mar-Apr;16(2):649-54
pubmed: 16681741
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365
Int J Gynecol Cancer. 2009 Nov;19(8):1407-11
pubmed: 20009898